GLPG
Galapagos N.V.
NASDAQ · Healthcare · Biotechnology · BE
$27.98
+1.71%Price chart
Jul 14Jul 17Jul 22Jul 27Jul 30Aug 4Aug 7Aug 12
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.7x
Market Cap
$1.84B
MomentumView details →
1D Return
+1.71%
YTD Return
−14.59%
RSI (14)
49.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.7x
Market Cap
$1.84B
RSI (14)
49.4
MomentumView details →
1D Return
+1.71%
YTD Return
−14.59%
SummaryUpdated Mar 1, 2026
Galapagos NV (NASDAQ:GLPG) is a Belgian integrated biopharmaceutical company founded in 1999 and headquartered in Mechelen, Belgium. The company went public in 2012 and has evolved from a drug discovery platform into a focused biotechnology company developing innovative therapies for high unmet medical needs. Originally operating across multiple therapeutic areas, Galapagos has undergone significant strategic transformation in recent years, narrowing its focus to oncology and immunology while divesting non-core assets. The company is currently planning a major corporate restructuring that will separate it into two distinct entities by mid-2025.
Similar companies
Latest newsMore news →
Lakefront Biotherapeutics NV repurchased 127,796 of its own shares between August 24 and August 28, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.3d agoLakefront Biotherapeutics NV repurchased 117,471 of its own shares between August 17 and August 21, 2026, under its buyback program announced on June 9, 2026, via a discretionary mandate to an independent intermediary.10d agoThe U.S. FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus, as announced by Lakefront Biotherapeutics NV on 24 August 2026.11d ago